Recent advances in the development of radionuclide labeled monoclonal antibodies as radiopharmaceuticals should result in commercially available products in the near future. This presentation describes mechanisms by which radiation can destroy cells, factors influencing the potential for successful treatment, concepts to understanding the use of radionuclide containing antibodies, etc. (Author/MLW)